Guardant Health Inc. stocks have been trading up by 13.38 percent after upbeat coverage highlighted its strong growth and innovation potential.
Click Here for a Millionaire's POV on Trading GH
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q1 sales at Guardant Health jumped 48% year over year to about $302M, fueled by 47% growth in oncology testing volumes and a huge surge in Shield screening revenue.
- Shield revenue climbed to $41.6M from $5.7M, with volumes up nearly 400%, and a nationwide Quest Diagnostics collaboration aims to drive even faster adoption.
- Management raised its FY26 revenue outlook to $1.30B–$1.32B, above prior guidance and Street expectations, while still projecting negative free cash flow.
- Major banks including Baird, JPMorgan, Barclays, and Piper Sandler lifted price targets on GH and kept bullish ratings; Evercore ISI inched its target higher but stayed more neutral.
- GH continues scaling operations, granting 143,898 RSUs to 267 new hires, while Co‑CEO AmirAli Talasaz sold 50,000 shares for about $5.0M but still holds roughly 2.1M shares indirectly.
Live Update At 14:02:36 EDT: On Wednesday, May 20, 2026 Guardant Health Inc. stock [NASDAQ: GH] is trending up by 13.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Guardant Health (GH) is trading like a classic high‑growth story. Over the last few weeks, GH has ripped from a close of $83.09 on 2026/04/28 to $111.33 on 2026/05/20. That’s a powerful uptrend, backed by real numbers, not just hype.
Q1 revenue came in around $302M, and full‑year trailing revenue sits near $982.0M. GH is still losing money, with an EBIT margin of about ‑42% and Q1 net loss of roughly $112.1M. For traders, that means GH is a “growth over profits” name. You’re betting on future scale, not current earnings.
Gross margin near 64.5% and a current ratio of 4.8 show GH has strong unit economics and plenty of liquidity to keep funding expansion. Free cash flow was about ‑$71.2M, so the cash burn is real, but the balance sheet carries roughly $989.3M in cash and $1.10B including short‑term investments.
More Breaking News
- ARM Stock Rallies As Wall Street Hikes AI-Fueled Targets
- Guardant Health Stock Climbs As Q1 Beat Fuels Bullish Targets
- RXT Stock Slips As Insider Files Form 144 Sale Notice
- NU Stock Drops As Earnings Miss Overshadows Massive Growth
Intraday on 2026/05/20, GH held higher lows and pushed from about $105 at the open to over $111 into the afternoon, showing steady dip‑buying interest. For active traders, GH is behaving like a momentum leader in the liquid biopsy and NGS space.
Why Traders Are Watching Guardant Health
Traders are glued to GH right now because the core business is accelerating fast. Guardant Health posted a standout Q1: sales up 48% year over year to roughly $302M, oncology testing volumes up 47%, and screening revenue from the Shield test soaring more than 600%. Shield alone jumped to $41.6M from $5.7M, with volumes up nearly 400%. That is what real product‑market fit looks like in diagnostics.
On top of that, GH signed a nationwide collaboration with Quest Diagnostics. For traders, this matters. Quest brings scale, distribution, and thousands of ordering doctors. If Shield gains traction across that network, screening revenue can become a second major growth engine alongside the Guardant360 and Guardant Reveal franchises.
Management leaned into this momentum by raising the FY26 revenue outlook to $1.30B–$1.32B, above prior guidance and consensus. They still expect negative free cash flow, but guidance calls for improvement versus 2025. In other words, GH is choosing to push growth now and deal with profitability later.
Wall Street noticed. Baird boosted its GH price target to $129 and kept an Outperform rating. JPMorgan and Piper Sandler each moved their targets up to $135 with Overweight ratings, while Barclays raised its target to $120 and stayed Overweight. Evercore ISI nudged its target from $90 to $95 but stuck with an In Line stance, and CFRA trimmed its target to $112 even as it reiterated Buy, citing ongoing losses and slightly lower margin guidance. That mix tells traders GH is widely respected as a leader, but the Street is still watching the path to profits.
Conclusion
Guardant Health has all the traits of a momentum growth name that active traders love to stalk. GH is putting up big top‑line numbers, with nearly $302M in Q1 revenue and Shield growing at triple‑digit rates. The Quest Diagnostics collaboration adds another catalyst that can extend the move as more primary‑care doctors gain access to GH’s screening technology.
At the same time, GH is not a clean, profitable story. Margins are still negative, free cash flow is in the red, and the balance sheet shows a stockholders’ deficit despite a hefty cash pile. CFRA’s lower $112 target and the note about continued losses underline that risk. Insider activity is mixed too: Co‑CEO AmirAli Talasaz sold 50,000 shares for about $5.0M, though he still controls roughly 2.1M shares indirectly. GH also granted 143,898 RSUs to 267 new employees, a sign of aggressive hiring that supports growth but adds dilution.
For traders, this comes down to discipline. GH’s chart is trending up, volume is supporting the move, and analyst price targets are resetting higher. But it remains a volatile, high‑beta biotech name. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your discipline. Cut losses quickly and let the best setups come to you.” That mindset lines up with another key trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. GH is one of those names to study closely, plan your trade, and treat every entry and exit as part of a well‑defined trading strategy, purely for educational and research purposes.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.